Biased Ligands. Better Drugs.

TRV130 Phase 2 bunionectomy full results

A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain

Eugene R. Viscusi, Lynn Webster, Michael Kuss, Stephen Daniels, James A. Bolognese, Seth Zuckerman, David G. Soergel, Ruth Ann Subach, Emily Cook, Franck Skobieranda

View PDF

Copyright © Trevena, Inc.